



Press Release

January 2, 2012

Corline adds important US and Australian IP within Regenerative Medicine

Swedish company Corline Systems AB, maker and distributor of a proprietary and unique heparin coating technology for use in Regenerative Medicine, has been granted approval of Patent Application No. 11/994,457 by the US Intellectual Property Office, and Patent Application No. 2,006,266,501 by Australian Government IP Australia.

“This IP approval is a break-through for Corline in two of the world’s largest and most influential markets for Regenerative Medicine. We know that our technology holds potential to radically improve treatments for patients that in many cases have no options in today’s healthcare. By merit of its broad applicability, the newly granted patents will form a cornerstone in how Corline may build its capabilities and competitive advantage in this fast evolving industry. All to the benefit of patients around the world”, comments CEO Henrik Nittmar.

The patents – both titled ‘Heparin Coating of Biological Tissue’ – cover methods for application and use of the company’s proprietary heparin coating technology for coating all types of biological tissue, such as living cells for transplantation, tissue segments and decellularized tissue matrices.

Corline is developing its technology for use in a multitude of clinical applications in the Regenerative Medicine space, both in partnership with industrial companies from many corners of the world, and together with international research groups in Europe, the US and Australia. A common denominator is that all projects use the same core technology, the one that now has gained improved protection by the newly granted patent applications.

One example of Corline’s internally developed project is that it has developed its unique heparin coating technology for application to Islets of Langerhans, and as such it can attenuate blood mediated inflammation reactions and save valuable donated cells from destruction when transplanted to patients. The Swedish Medical Products Agency has given its approval to start clinical trials for this promising technology.

“We recently received funding from the EU commission, and on the backbone of that we are moving into clinical trials with our core technology in Europe. In parallel we are marketing our technology to several partners in the huge US market, and the newly granted patents are a necessary basis for future investments to realize such a plan. So this is a very good start for Corline in the new year”, concludes CEO Henrik Nittmar.

About Corline and CHS

Corline is a biotechnology company based in Uppsala, Sweden, that develops, manufactures and distributes a proprietary patent protected heparin conjugate surface (CHS) that can be used both for medical devices and for Regenerative Medicine (cell therapy and tissue engineering). In 2008, the market for Regenerative Medicine totaled a 1.5 bn USD turnover, with a 90 % share being focused in the US. The US based market analysis company Life Science Intelligence, estimates the total potential to be over 100 bn USD.

CHS can be used to coat living cells and tissue without compromising their biological functions. CHS helps attenuate the local inflammation that is formed on and around grafts at transplantation, and promotes new blood vessels to grow more quickly to support the graft. For the patient, CHS potentially means better clinical outcome and a more rapid recovery from treatment.

Corline conducts pre-clinical and clinical studies within a number of cell and tissue therapy areas. These studies are a first step towards realizing the company's vision of having its CHS platform technology widely used within the future Regenerative Medicine market. The CHS technology is protected by more than 20 granted and pending patents.

Corline is a privately held company, financially backed by members of the Crafoord family, primarily known for the development of Swedish medical device company Gambro (founded by Holger Crafoord), and Lars Sunnanväder, a well-known entrepreneur who has founded several medical device and biotechnology companies, e.g. heart/lung assist and coronary surgical device manufacturer Jostra, lung assist device manufacturer Novalung, Jotec, Jolife, Joline and other companies within this field.

For more information, please contact:

Henrik Nittmar, CEO
Tel. +46 (0)18 71 30 90
henrik.nittmar@corline.se
www.corline.com

Corline Systems AB
Box 956
715 09 Uppsala
SWEDEN